Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Hypersensitivity Syndrome (DRESS) With Tegeline® (Human Immunoglobulin)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age \>= 18~* Cutaneous and/or mucous eruption~* Polyadenopathy~* Body temperature \> 38°C~* Hematology disorders : Hypereosinophily \> 1.5 G/l, lymphocytosis \> 5G/l, atypical blood lymphocytes~* Consent obtained from patient~Exclusion Criteria:~* Age \< 18~* No consent obtained from patient~* IgV allergy~* Dress with very sérious visceral attack and vital diagnostic (sharp cardiac insufficiency, sharp respiratory insufficiency, hepatic insufficiency, sharp renal insufficiency)~* Oral therapy or immunosuppressive therapy (Methotrexate, cyclosporine, cyclophosphamide, etc.)~* IgA deficiency,~* MCI \>=35~* Sharp renal insufficiency before Dress with creatinaemia \< 60 ml/min (Cockroft)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).